Table 2.
Tuberculosis locations according to [18F]FDG-PET/CT data and values of PET/CT quantitative criteria ∑SUV and MSUV at 3 time points.
| PET1 (n = 42) | PET2 (n = 35) | PET3 (n = 8) | ||
|---|---|---|---|---|
| Presence of [ 18 F]FDG abnormal Hot spots evocative of TB lesions | 41 (97.6%) | 29 (82.8%) | 7 (87.5%) | |
| Lymph nodes | Cervical | 24 (58.5%) | 10 (34.5%) | 3 (42.9%) |
| Mediastinal | 27 (65.9%) | 10 (34.5%) | 3 (42.9%) | |
| Axillary | 8 (19.5%) | 4 (13.8%) | 0 (0.0%) | |
| Abdominal, pelvic | 16 (39.0%) | 4 (13.8%) | 0 (0.0%) | |
| Inguinal | 3 (7.3%) | 1 (3.4%) | 0 (0.0%) | |
| Bone | Spine | 14 (34.1%) | 4 (13.8%) | 0 (0.0%) |
| Bassin | 6 (14.6%) | 1 (3.4%) | 0 (0.0%) | |
| Sup | 1 (2.4%) | 0 (0.0%) | 0 (0.0%) | |
| Inf | 3 (7.3%) | 2 (6.9%) | 0 (0.0%) | |
| Other | 5 (12.2%) | 0 (0.0%) | 1 (14.3%) | |
| Lungs | 11 (26.8%) | 5 (17.2%) | 1 (14.3%) | |
| Liver | 3 (7.3%) | 0 (0.0%) | 0 (0.0%) | |
| Spleen | 3 (7.3%) | 0 (0.0%) | 0 (0.0%) | |
| GUT | 3 (7.3%) | 1 (3.4%) | 0 (0.0%) | |
| ENT | 2 (4.9%) | 0 (0.0%) | 0 (0.0%) | |
| Muscular | 16 (39.0%) | 6 (26.7%) | 0 (0.0%) | |
| Skin | 4 (9.8%) | 1 (3.4%) | 0 (0.0%) | |
| Abdominal abcess | 1 (2.4%) | 0 (0.0%) | 1 (14.3%) | |
| Other | 4 (9.8%) | 2 (6.9%) | 3 (42.9%) | |
| ∑SUV | Mean (std) | 39.0 (28.7%) | 8.9 (8.2%) | 4.7 (3.1%) |
| (Patients with abnormal PET) | Median (IQR) | 32.0 [21.1–47.8] | 6.1 [3.1–12.5] | 4.0 [2.3–8.0] |
| MSUV | Mean (std) | 7.0 (2.8) | 3.3 (2.1) | 2.8 (2.6) |
| (Patients with abnormal PET) | Median (IQR) | 6.6 [4.9–9.2] | 3.1 [2.0–5.0] | 2.1 [1.1–4.0] |
| ∑SUV | Mean (std) | 38.1 (29.0) | 7.3 (8.1) | 4.1 (3.3) |
| All patients | Median (IQR) | 31.5 [19.6–47.8] | 5.4 [0–11.2] | 3.8 [1.1–7.1] |
| MSUV | Mean (std) | 6.8 (2.9) | 2.7 (2.3) | 2.4 (2.6) |
| All patients | Median (IQR) | 6.5 [4.8–9.2] | 2.7 [0.0–4.7] | 1.6 [0.6–3.4] |
PET1, [18F]FDG-PET/CT performed at initial diagnosis; PET2, [18F]FDG-PET/CT performed at the end of treatment; PET3, [18F]FDG-PET/CT performed 6 months after the end of treatment.